In the absence of a submission from the holder of the marketing authorisation.
bosentan (Traceleer®), is not recommended for use within NHS Scotland for the treatment of pulmonary arterial hypertension (PAH) WHO functional class II.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHS Scotland.
Download detailed advice24KB (PDF)
- Medicine name:
- bosentan (Tracleer)
- SMC ID:
- pulmonary arterial hypertension (PAH) WHO functional class II
- Pharmaceutical company
- Actelion Pharmaceuticals UK Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Non submission
- Not recommended
- Date advice published:
- 10 November 2008